Science Explorer Back to mapMap
Discussion
Topic · Geriatrics and Gerontology

Pharmaceutical Practices and Patient Outcomes

Pharmaceutical Practices and Patient Outcomes is a research topic within Geriatrics and Gerontology. Science Explorer counts 44k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the challenges and consequences of polypharmacy, inappropriate medication use, and adverse drug events in the elderly population. It explores topics such as potentially inappropriate prescribing, pharmacist interventions, medication reconciliation, deprescribing, and the impact of anticholinergic burden. The research aims to address the complexities of medication management in older adults and improve patient outcomes.

  • Polypharmacy
  • Inappropriate Medication Use
  • Elderly
  • Adverse Drug Events
  • Potentially Inappropriate Prescribing
  • Pharmacist Intervention
  • Medication Reconciliation
  • Deprescribing
  • Anticholinergic Burden
  • Clinical Pharmacy Services
Research works
44k
fractional, since 1950
In the world top 10%
4.5k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+11%
the tick is no change
Largest producer
United States
42% of the 10 largest, 2022-now
Pharmaceutical Practices and Patient Outcomes

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Pharmaceutical Practices and Patient Outcomes research?

By volume, the United States and the United Kingdom publish the most (2.6k and 758 works in 2022-now).

By volume, 2022-now

  1. 1 United States 2.6k works
  2. 2 United Kingdom 758 works
  3. 3 India 534 works
  4. 4 France 412 works
  5. 5 Australia 411 works
  6. 6 Spain 333 works
  7. 7 Indonesia 313 works
  8. 8 Canada 300 works
  9. 9 China 293 works
  10. 10 Saudi Arabia 283 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 41.9%United Kingdom: 12.1%India: 8.5%France: 6.6%6 others listed: 30.9%42%largest
United States2,626 · 41.9%United Kingdom758 · 12.1%India534 · 8.5%France412 · 6.6%6 others listed1,933 · 30.9%

Shares of the rows listed above, not of the whole node.

Which institutions lead Pharmaceutical Practices and Patient Outcomes research?

By volume in 2022-now, University of North Carolina at Chapel Hill publishes the most Pharmaceutical Practices and Patient Outcomes research, followed by Harvard University and United States Department of Veterans Affairs.

By volume, 2022-now

  1. 1 University of North Carolina at Chapel HillUnited States 85 works
  2. 2 Harvard UniversityUnited States 62 works
  3. 3 United States Department of Veterans AffairsUnited States 60 works
  4. 4 The University of SydneyAustralia 54 works
  5. 5 University College CorkIreland 46 works
  6. 6 University of TorontoCanada 42 works
  7. 7 Johns Hopkins UniversityUnited States 37 works
  8. 8 Monash UniversityAustralia 37 works
  9. 9 American Pharmacists AssociationUnited States 36 works
  10. 10 InsermFrance 34 works

Who are the leading researchers in Pharmaceutical Practices and Patient Outcomes?

The most-cited researchers publishing on Pharmaceutical Practices and Patient Outcomes include David Moher, Christopher J L Murray and George Davey Smith.

  1. 1 David Moher Canada 898k citations
  2. 2 Christopher J L Murray United States 583k citations
  3. 3 George Davey Smith United Kingdom 435k citations
  4. 4 Ali H. Mokdad United States 429k citations
  5. 5 Julian P. T. Higgins United Kingdom 390k citations
  6. 6 John J.V. McMurray United Kingdom 349k citations
  7. 7 Hermann Brenner Germany 343k citations
  8. 8 Mika Kivimäki United Kingdom 318k citations
  9. 9 John P. A. Ioannidis United States 317k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Pharmaceutical Practices and Patient Outcomes?

The most cited paper in Pharmaceutical Practices and Patient Outcomes is "Prediction of Creatinine Clearance from Serum Creatinine" (Donald W. Cockcroft, Henry Gault, 2008), with 15,456 citations. Next come "A method for estimating the probability of adverse drug reactions" (11,879) and "Adherence to Medication" (8,018).

Most cited papers
#PaperReleasedCitations
1 Prediction of Creatinine Clearance from Serum Creatinine Donald W. Cockcroft, Henry Gault · ˜The œNephron journals/Nephron journals 28 Nov 2008 15,456
2 A method for estimating the probability of adverse drug reactions C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics Aug 1981 11,879
3 Adherence to Medication Lars Osterberg, Terrence F. Blaschke · New England Journal of Medicine 3 Aug 2005 8,018
4 Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia Jeffrey Alan Lieberman, T. Scott Stroup, Joseph P. McEvoy et al. · New England Journal of Medicine Open access 19 Sep 2005 5,930
5 Incidence of Adverse Drug Reactions in Hospitalized Patients Jason Lazarou, Bruce H. Pomeranz, Paul Corey · JAMA 15 Apr 1998 4,842
All 99 most cited papers, with filters and sorting

Where is Pharmaceutical Practices and Patient Outcomes research done?

The largest centres of Pharmaceutical Practices and Patient Outcomes research in 2022-now are London (United Kingdom), Riyadh (Saudi Arabia), Melbourne (Australia) and Paris (France).

Largest cities, 2022-now

  1. 1 LondonUnited Kingdom 171 works
  2. 2 RiyadhSaudi Arabia 110 works
  3. 3 MelbourneAustralia 89 works
  4. 4 ParisFrance 89 works
  5. 5 Washington D.C.United States 85 works
  6. 6 SydneyAustralia 85 works
  7. 7 BostonUnited States 84 works
  8. 8 Chapel HillUnited States 81 works
  9. 9 New YorkUnited States 79 works
  10. 10 TokyoJapan 68 works
See Pharmaceutical Practices and Patient Outcomes on the map

Where is the best place to study Pharmaceutical Practices and Patient Outcomes?

Among universities, judged by research, University College Cork, Qatar University and Harvard University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 21.72%fractional works in this field (log) →share of work in the world top 10% →Qatar UniversityThe University of Sy…Harvard UniversityUniversity College C…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1University College CorkIreland 71.617.5%17.7×46 +81.2%
2Qatar UniversityQatar 68.124.2%12.9×32 +45.3%
3Harvard UniversityUnited States 66.817.8%2.3×62 +14.7%
4The University of SydneyAustralia 64.423.3%5.1×54 -15.3%
5Sichuan UniversityChina 64.034.7%1.0×20 +390.0%
6University of GroningenNetherlands 59.622.9%2.8×17 +23.4%
7King Saud UniversitySaudi Arabia 58.717.2%3.5×30 +13.9%
8Qassim UniversitySaudi Arabia 57.226.2%5.2×12 +101.7%
9Trinity College DublinIreland 57.113.6%8.2×29 +17.2%
10Newcastle UniversityUnited Kingdom 57.019.8%5.2×22 +101.6%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Pharmaceutical Practices and Patient Outcomes, country by country

Is Pharmaceutical Practices and Patient Outcomes research growing?

Output in 2022-2025 was 11% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Pharmaceutical Practices and Patient Outcomes.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Pharmaceutical Practices and Patient Outcomes as a percentage of every work published that year, 0.045% in 2024.

still counting0.020%0.040%0.060%Pharmaceutical Practices and Patient Outcomes0.042% in 202519801990200020102020

Fractional works of Pharmaceutical Practices and Patient Outcomes over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Pharmaceutical Practices and Patient Outcomes10.1% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Pharmaceutical Practices and Patient Outcomes. Posts are plain text and can be reported.